Skip to content

Understanding how critical illness and liver disease affect blood clotting

PLAtelet function in Critical Illness and liver Disease (PLACID)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN11565046
Enrollment
30
Registered
2024-05-22
Start date
2024-05-15
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease, critical illness, platelet function Haematological Disorders

Interventions

This is an observational study, there are no interventions. The following is a brief summary of our methodologies. A total of 30 patients will be recruited for this study from the ICU at the Royal B

Sponsors

Royal Berkshire NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 24/05/2024: 1. Admitted to ICU at the Royal Berkshire Hospital 2. Aged 18 years old and above 3. Evidence of established liver disease, or acute liver dysfunction related to underlying illness, as determined by the clinicians caring for the patient at the time of eligibility assessment. Previous participant inclusion criteria: 1. Known liver disease or 2. Acute liver dysfunction

Exclusion criteria

Exclusion criteria: 1. Patients on P2Y12 inhibitors (including clopidogrel, ticagrelor and prasugrel) 2. Patients on treatment-dose anticoagulation, including warfarin or novel anticoagulant drugs 3. Patients under 18 years of age 4. Active or recent malignancy (< 1 year) or on active treatment

Design outcomes

Primary

MeasureTime frame
Platelet reactivity measured using Platelet Phenomics Analysis (Flow Cytometry and Thrombus formation under flow) combined with mathematical analysis, correlated according to liver disease type, burden, and stage, in blood collected during the study

Secondary

MeasureTime frame
The following secondary outcome measures will be assessed in blood collected during the study: 1. Thrombus size generated measured using an in vitro thrombus formation assay 2. Clotting parameters measured using thromboelastography and related haemostatic assays 3. Platelet receptor levels measured using flow cytometry 4. Signalling protein absolute levels and phosphorylation state measured using proteomic analysis 5. Signalling-pathway-specific experiments including modelling changes in cell lines

Countries

England, United Kingdom

Contacts

Public ContactTyler Horn
tyler.horn@royalberkshire.nhs.uk+44 (0)118 378 8169

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 1, 2026